Middle East Pharmaceutical Industries Company (TADAWUL:4016)

Market Cap	2.55B
Revenue (ttm)	394.00M
Net Income (ttm)	79.85M
Shares Out	20.00M
EPS (ttm)	3.99
PE Ratio	31.96
Forward PE	n/a
Dividend	2.50 (1.99%)
Ex-Dividend Date	May 4, 2025

Volume	67,155
Average Volume	43,110
Open	130.00
Previous Close	127.60
Day's Range	128.00 - 131.00
52-Week Range	107.00 - 153.80
Beta	n/a
RSI	43.77
Earnings Date	May 7, 2025

About TADAWUL:4016

Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export. It offers medicines and preparations used to treat skin diseases, skin creams, and skin care products; respiratory, central nervous, digestive, and musculoskeletal system medicines; urinary and reproductive system drugs; disinfectants; and various therapeutic ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 632
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4016

Financial Performance

In 2024, TADAWUL:4016's revenue was 394.00 million, an increase of 16.42% compared to the previous year's 338.44 million. Earnings were 79.85 million, an increase of 21.30%.